1. Stats
  2. USPTO
  3. TC 1600
  4. Group 1640
  5. Art Unit 1646
  6. Examiner Halvorson

Examiner Halvorson Mark

1646-HALVORSON-MARK

Employment Information

Art Unit:1646 — Drug, bio-affecting and body treating compositions
Group:1640 — Immunology including antibodies, B&T lymphocytes, antigen presenting cells and Gram-positive/Negative Bacteria, Parasitic and Fungal Immunology
Classes: 424 — Drug, bio-affecting and body treating compositions
435 — Chemistry: molecular biology and microbiology
530 — Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
514 — Drug, bio-affecting and body treating compositions
506 — Combinatorial chemistry technology: method, library, apparatus
536 — Organic compounds -- part of the class 532-570 series
436 — Chemistry: analytical and immunological testing
604 — Surgery
702 — Data processing: measuring, calibrating, or testing
Phone:(571) 272-6539
Email:mark.halvorson@uspto.gov
Location:VA 22314
Title:Pat Examnr (Biolgy)
Service:20 years
Grade:GS-14

Grant Rate and Difficulty Ranking

85
3-Year Grant rate: 43% over 257 cases
Difficulty: Very Hard
Difficulty Percentile: 85th

With Examiner Halvorson, you have a 43% chance of getting an issued patent by 3 years after the first office action. Examiner Halvorson is a very hard examiner and in the 85th percentile across all examiners (with 100th percentile most difficult).

Grant Rate

Grant Rate Timeline

Below is the grant rate timeline for Examiner Halvorson, where the timeline is relative to the date of the first office action. The three-year grant rate is the percentage of applications granted at three years after the first office action.

Comparison with Art Unit 1646

Examiner Halvorson's grant rate is lower than that of Art Unit 1646 and lower than that of the USPTO.

Average Office Actions Per Grant
Examiner Halvorson 1.7
Art Unit 1646 1.5

Interview Benefit

Grant Rate without Interview

Examiner Halvorson has granted 96 of 219 cases without any applicant-requested interviews for a grant rate of 44%.

Grant Rate with Interview

Examiner Halvorson has granted 15 of 38 cases with at least one applicant-requested interview for a grant rate of 39%.

Interview Benefit

With Examiner Halvorson, conducting an interview decreases your chance of getting a patent granted by 11%.

Recent Dispositions

Recent Dispositions

Number Title OA Rejections Status IFW
17292926 Methods And Compositions For Prediction Of Response To A Therapy Of An Inflammatory Bowel Disease Rejection information available with a Premium Stats subscription. See our pricing. Patented View
18388099 Protein Biomarker And Uses Thereof Patented View
17101522 Neoantigen Identification, Manufacture, And Use Abandoned View
17741967 Anti-Tim-3 Antibodies And Compositions Patented View
17620036 Compositions Patented View
18322545 Anti-Tigit Antibodies, Anti-Pvrig Antibodies And Combinations Thereof Patented View
17788149 Compositions And Uses Thereof Abandoned View
17753682 Ykl-40-Targeting Human Monoclonal Antibody Patented View
16007146 Method Of Treatment Of Cancer Abandoned View
18214434 Means And Methods For Diagnosing Pancreatic Cancer Abandoned View
17750341 Single Domain Antibodies Directed Against Intracellular Antigens Patented View
18380117 Nucleic Acid Biomarker And Use Thereof Patented View
18177334 Anti-Fam19a5 Antibodies And Uses Thereof Patented View
17530974 Antibodies And Use Thereof Patented View
17516794 Subcutaneous Dosing Of Anti-Cd20/anti-Cd3 Bispecific Antibodies Patented View
17842915 Dual Antigen-Induced Bipartite Functional Complementation Abandoned View
17292179 Intralesional Administration Of Pd-1 Inhibitors For Treating Skin Cancer Patented View
16644934 Neoantigen Identification For T-Cell Therapy Abandoned View
18182682 Fusion Proteins Having A Toxin And Cancer Marker, Nanoparticles, And Uses Related Thereto Patented View
17455192 Bispecific Antibodies For Use In Treatment Of Nlrc4-Gof Inflammasomapathy Patented View
17450318 Identification And Use Of Novopeptides For The Treatment Of Cancer Abandoned View
18596217 Anti-Influenza Neuraminidase Monoclonal Antibodies And Uses Thereof Patented View
18351374 Materials And Methods For Performing Histochemical Assays For Human Pro-Epiregulin And Amphiregulin Patented View
17118594 Novel Fungal Toxins And Methods Related To The Same Abandoned View
18499484 Cancer Stem Cell-Targeted Cancer Therapy Abandoned View
18590121 Biomarkers And Methods Of Treating Pd-1 And Pd-L1 Related Conditions Abandoned View
18488634 Combination Treatment Of Cd38-Expressing Tumors Abandoned View
17737453 Use Of Tm9sf4 As A Biomarker For Tumor Associated Exosomes Abandoned View
17005051 Anti-Cd73 Antibodies Patented View
17527011 Nucleobase Editors And Uses Thereof Patented View
17609359 Dosage Regimens For A Combination Of Anti-Dr5 Antibodies For Use In Treating Cancer Abandoned View
17604356 Peptides In Combination With Immune Checkpoint Inhibitors For Use In Treatment Of Cancer Abandoned View
17270924 Therapeutic Agents Comprising Nucleic Acids And Car-Modified Immune Cells, And Uses Thereof Patented View
18181802 Method For Identifying Neoantigens On Cancer Cells By Using Xenoantibodies Abandoned View
17717985 Methods Of Detecting Cancer Patented View
16813371 Formulations For Neoplasia Vaccines Abandoned View
18164444 Binding Proteins 1 Patented View
17692787 Hla Class Ii-Restricted T Cell Receptors Against Mutated Ras Patented View
17354555 T Cell Receptors With Improved Pairing Patented View
16838651 Methods For Detecting Circulating Tumor Cells In Non-Small Cell Lung Cancer Abandoned View
17826948 Autoantibody Biomarkers Of Ovarian Cancer Patented View
18192226 Compositions And Methods For Treating Solid Tumors Abandoned View
17936398 Use Of Lenvatinib Plus Anti-Pd-1 Monoclonal Antibody In Preparation Of Anti-Hepatoma Drug Abandoned View
17878533 Anti-Tumour Response To Modified Self-Epitopes Patented View
16956797 Bispecific Antibody Construct Directed To Muc17 And Cd3 Patented View
17830027 Reducing Blood Glucose, Insulin Resistance, Or Hyperlipidemia Through Rlip76 Partial Depletion Abandoned View
17398846 Methods For The Detection And Quantification Of Circulating Endothelial Cells Abandoned View
17706905 Methods Of Prognosis Abandoned View
17147681 Screening And Assessment Of Potentially Malignant Oral Lesions Patented View
15734205 Biomarkers, Uses Thereof For Selecting Immunotherapy Intervention, And Immunotherapy Methods Abandoned View

Appeals Statistics

Purchase Subscription

Subscribe to Premium Examiner Statistics for unlimited access for your law firm.

Disclaimer: We do not provide any guarantees as to the accuracy of the statistics presented above and under
no circumstances will we be liable for any outcome resulting from your reliance on the above statistics.